LAWRENCE, Mass. and PHOENIX, Feb. 20, 2011 /PRNewswire/ — NxStage® Medical, Inc. (Nasdaq:
NXTM), a leading manufacturer of innovative dialysis products,
today announced the latest interim results from its ongoing FREEDOM
study which show an increase in overall quality of life benefits,
significant improvement in overall sleep quality and a marked
improvement in Restless Legs Syndrome (RLS) symptoms experienced by
patients after 12 months of daily home hemodialysis with the
NxStage System One™. The study results were presented during
the Annual Dialysis Conference in Phoenix, Arizona. The
ongoing FREEDOM study is the largest study of its kind to measure
the clinical and economic benefits of daily home hemodialysis
treatment, as compared to conventional, thrice-weekly in-center
hemodialysis treatment for patients requiring dialysis therapy.
“These latest 12-month results are extremely encouraging. The
analysis shows the quality of life benefits eligible patients
experience at month four continue and sometimes strengthen by month
12. These benefits are dramatic and can be truly life-changing,”
said Dr. Frederic Finkelstein MD, Chief of Nephrology at the
Hospital of St. Raphael in New Haven, Conn. and Clinical Professor
of Medicine at Yale University Medical School as well as an
investigator on the FREEDOM study. “These improvements in mental
and physical scores suggest that daily hemodialysis leads to an
overall healthier and happier patient.”
The interim analysis of the FREEDOM study shows that daily home
hemodialysis is associated with clear improvements in quality of
life benefits sustained throughout a 12-month period, as measured
by the SF-36v2 Health Survey. Results show:
Significant improvements in both mental health scores (Mental
Component Summary) and physical health scores (Physical Component
Summary)
‘/>”/>
SOURCE